This microburst learning enduring program aims to improve neurologists and neurology-focused NPs and PAs knowledge of novel mechanisms of action for and evidence on emerging treatments that may address unmet needs in Alzheimer’s disease-related psychosis. Education on the latest clinical trials and emerging therapies targeting ADP show promise in reducing symptoms with fewer side effects. As a result of this educational curriculum, learners will be better to: 1. Recognize the unmet therapeutic needs in managing patients with Alzheimer’s disease psychosis (ADP); 2. Review the rationale for using therapies with novel mechanisms for the treatment of patients with ADP; 3. Describe the implications of the latest data on novel therapies for managing patients with ADP. Learners will also have the opportunity to view a list of all sessions to allow easy access to those of greatest interest. Downloadable slides will be included and available for learners to download for use in clinical practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/UYY
- Start Date: 2024-09-17 05:00:00
- End Date: 2024-09-17 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 153371.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all